Business
RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S
Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.
About this update from Amgen Inc.
[{"type":"text","content":"Ro's and Amgen's research will focus on barriers to care and improving access to treatment","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.","length":417,"tagName":"p"},{"type":"image","alt":"Ro and Amgen to collaborate on research focused on insurance coverage and improving access to GLP-1 treatment.","displaySize":"","headline":null,"caption":"Ro and Amgen to collaborate on research focused on insurance coverage and improving access to GLP-1 treatment.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/cbc5664ecda948d0736c876e8bfb3959"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZzR_5i8f8_DWg8a.PgW..w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cbc5664ecda948d0736c876e8bfb3959","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2860132/Ro_and_Amgen_to_collaborate.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""GLP-1s can be life-changing for those who can get treatment, but real impact requires scale – which means dramatically improving access for the millions of Americans who could benefit from care," said Zach Reitano, CEO and Co-founder of Ro. "By studying Ro's real-world, de-identified data we can generate insights that help us build tools that empower patients to overcome barriers to care and get more personalized support, laying the groundwork for broader access as innovators like Amgen bring the next generation of medicines to people living with obesity and related conditions."","length":610,"tagName":"p"},{"type":"text","content":"As GLP-1s help to transform the obesity treatment landscape, insurance coverage for the medications has remained a key hurdle for patients and providers. While prior research has focused on policy-level data, Ro's and Amgen's will importantly e...